mod­el of duck hepati­tis B virus (45nm)

ARTESMETAVAX® plat­form is designed for the devel­op­ment of high­ly immuno­genic sub­unit vac­cines in human and ani­mal health. It is based on enveloped virus like par­ti­cles (VLP) derived from the recom­bi­nant sur­face anti­gen of the duck hepati­tis B virus (dS) as scaffold.

METAVAX® sup­ports effi­cient expres­sion, fold­ing and pre­sen­ta­tion of the tar­get anti­gen on the sur­face of virus-like par­ti­cles. The result­ing chimeric VLP enhances recog­ni­tion and uptake by anti­gen pre­sent­ing cells and results in a potent immune response against the tar­get anti­gen. Com­bined with ARTES’ yeast expres­sion plat­form Hansenu­la poly­mor­pha, it builds a con­vinc­ing approach for eco­nom­ic pro­duc­tion of safe and effi­ca­cious vaccines.

Adju­vant-free vac­cine can­di­dates address­ing dis­eases like avian and swine flu, malar­ia and HIV have been test­ed in pre­clin­i­cal stud­ies and were found to be safe, gen­er­al­ly well tol­er­at­ed and high­ly immunogenic.

The tech­nol­o­gy plat­form is well estab­lished in dif­fer­ent cus­tomers’ ani­mal vac­cine devel­op­ment projects.

METAVAX® at a glance:

  • well suit­ed for human and vet­eri­nary vaccines
  • pre­sen­ta­tion of large tar­get anti­gens and con­for­ma­tion­al epitopes
  • ver­sa­tile expres­sion of tar­gets as e.g. N- or C‑terminal fusion proteins
  • rapid fea­si­bil­i­ty stud­ies by gener­ic process­es and analytics